Cooley advised Artiva Biotherapeutics, a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers, on its upsized $167 million initial public offering. Partners Carlos Ramirez and Charlie Kim led the Cooley team advising Artiva.